Grifols is readying an approval run at U.S. and European regulators on the back of a phase 3 win for the Spanish plasma medicine producer’s concentrated form of a blood clotting factor.

The trial included 25 people with pancreatic or colorectal cancer who had previously undergone surgery, seven of whom also had received radiation therapy. They were given up to 10 doses of the vaccine known as ELI-002, and the results were promising: 84 percent of all participants had positive T cell responses—and all of those who received higher doses had a response. The results of the trial, which was funded by Boston-based biotech company Elicio Therapeutics, were published in Nature Medicine.

Lumos Pharma is developing LUM-201 (ibutamoren) for the treatment of moderate pediatric growth hormone deficiency. PGHD is a rare disorder in which the body doesn’t make enough growth hormone.

Cerevance has shown that “we can tamp down the inflammation response, or the inflammasome, but keep all the other surveillance and other aspects of microglia still functioning as they should.” The company is now conducting a Phase I study of CVN293, with topline data expected in the second quarter of 2024.

Some venture firms are pumping money into publicly traded biotechnology companies, as falling share prices prompt these investors to expand their search for bargains to the public markets.

A vaccine for the postsurgical treatment of KRAS-mutated pancreatic and colorectal cancers, ELI-002, is showing promising early study results — but any potential broad commercial availability of the drug is likely several years away, as one researcher tells CURE®.

As Elicio Therapeutics awaits a phase 2 readout of its lymph node-targeting therapeutic cancer vaccine in humans, the biotech has published fresh preclinical data showing the same tech boosted the efficacy of T cell receptor-modified T-cell (TCR-T) therapy in mice.

Lumos Pharma is dedicated to transforming the treatment landscape for rare pediatric diseases like PGHD. Lumos Pharma’s approach is not just about creating new drugs; it’s about rethinking the entire patient experience, prioritizing ease of use and minimizing the treatment burden on young patients and their families. Their work exemplifies a broader shift in the pharmaceutical industry towards patient-centric drug development — a paradigm that places the needs and well-being of patients at the forefront of every stage of the drug development process.